enGene Holdings Inc. (ENGN)

Market Cap	169.16M
Revenue (ttm)	n/a
Net Income (ttm)	-79.88M
Shares Out	51.11M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,774
Open	3.620
Previous Close	3.680
Day's Range	3.260 - 3.660
52-Week Range	2.650 - 11.000
Beta	-0.41
Analysts	Buy
Price Target	23.29 (+607.9%)
Earnings Date	Sep 9, 2025

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Summary

According to 7 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $23.29, which is an increase of 607.90% from the latest price.

Price Target

$23.29

(607.90% upside)

Analyst Consensus: Buy